ArticleScientific reports2026
Influence of rhBMP-2 and rhBMP-7 in fibrin on osseointegration of SLA implants: a preclinical evaluation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This in vivo study investigated the effect of recombinant human bone morphogenetic proteins-2 and -7 (rhBMP-2 and rhBMP-7) in both contained and non-contained defects on the osseointegrative capacity of sandblasted, large-grit and acid-etched (SLA) titanium implants in a rabbit tibia model. 32 SLA titanium implants were divided into SLA, SLA-F (with fibrin matrix), SLA-F-rhBMP-2 and SLA-F-rhBMP-7 groups. Implants were inserted into the tibiae of eight rabbits, with four rabbits euthanized at 2 and 8 weeks (n = 4). Fluorescent bone labeling procedure was conducted for the rabbits that would be euthanized 8 weeks post-implant placement, injecting tetracycline, xylenol orange and calcein blue every 2 weeks. Histomorphometric analysis was used to measure the height of new bone, periodic bone formation (PBF), bone-to-implant contact (BIC) and bone area (BA) ratios. All data were analyzed using one-way ANOVA with Tukey's post hoc test at a significance level of 0.05. SLA-F-rhBMP-2 group exhibited significantly greater new bone formation compared to SLA-F group at 8 weeks at the supracrestal peri-implant region (P = 0.048). Conversely, all groups showed similar bone healing quality at the interface between the implants and the existing bone. No significant differences were found in the PBF, BIC or BA values. Within the limitations of this preclinical study, fibrin-delivered rhBMP-2 significantly increased bone formation in supracrestal peri-implant regions, which can be interpreted as non-contained defects. At the bone-implant interface, neither rhBMP-2 nor rhBMP-7 added benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.